Literature DB >> 9178954

Effects of excitatory amino acids on cerebral oxygen consumption and blood flow in rat.

X Lu1, A K Sinha, H R Weiss.   

Abstract

This investigation tested the importance of excitatory amino acids' effects on regional cerebral O2 consumption and the concomitant changes in cerebral blood flow (rCBF) in isoflurane anesthetized rats. In the glutamate or N-methyl-D-aspartate (NMDA) groups, 10(-2) M glutamate or NMDA was topically applied to the right cortex and the left cortex was used as a control. One mg/kg dizocilpine maleate (MK-801), a non-competitive NMDA receptor antagonist, was administered (iv) to the MK-801 group and saline was given to the control group. Cortical rCBF was determined using 14C-iodoantipyrine and regional O2 extraction was measured microspectrophotometrically. Cerebral O2 consumption increased 77% after glutamate (contralateral cortex: 9.0 +/- 1.1 ml O2/min/100 g, glutamate treated cortex: 15.9 +/- 3.9), while a 46% increase was observed with the same concentration of NMDA (contralateral cortex: 9.8 +/- 2.0, NMDA treated cortex: 14.3 +/- 5.5). After MK-801, the O2 consumption decreased to 37% of the control value (control cortex: 7.0 +/- 1.3, MK-801 treated cortex: 2.6 +/- 3.9). MK-801 significantly decreased cerebral O2 extraction from 7.1 +/- 1.3 ml O2/100 ml (control cortex) to 5.3 +/- 0.6 (MK-801 treated cortex). However, there was no significant difference in cerebral O2 extraction between treated and contralateral cortex in either the glutamate or NMDA groups. The increase in O2 consumption caused by glutamate or NMDA was coupled with increased rCBF. Glutamate increased rCBF from 95 +/- 5 ml/min/100 g (contralateral cortex) to 165 +/- 31 (treated cortex), while NMDA increased rCBF from 114 +/- 12 (contralateral cortex) to 178 +/- 60 (treated cortex). MK-801 decreased O2 consumption with a lesser decrease of rCBF. The rCBF was 48 +/- 9 in the MK-801 treated cortex and 99 +/- 22 in the control cortex. Some substances produced by the activation of NMDA receptors may be related to the coupling of cerebral metabolism and blood flow, since after blockade of NMDA receptors with MK-801, this relationship is uncoupled. These findings suggest that glutamatergic processes have a major effect on cerebral O2 consumption and that this is at least partly due to NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9178954     DOI: 10.1023/a:1027354110563

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  35 in total

1.  In vivo binding and autoradiographic imaging of (+)-3-[125I]Iodo-MK-801 to the NMDA receptor-channel complex in rat brain.

Authors:  E G Gibson; H D Burns; H H Thorpe; W S Eng; R Ransom; H Solomon
Journal:  Int J Rad Appl Instrum B       Date:  1992-04

2.  Effects of isoflurane on transport across the blood-brain barrier.

Authors:  O Z Chi; M Anwar; A K Sinha; H M Wei; S L Klein; H R Weiss
Journal:  Anesthesiology       Date:  1992-03       Impact factor: 7.892

3.  Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain.

Authors:  J Garthwaite; S L Charles; R Chess-Williams
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

4.  Cerebrovasodilatation of metabolic and non-metabolic origin elicited by chemical stimulation of the lateral periaqueductal gray matter in anaesthetized rats.

Authors:  M Nakai; M Maeda
Journal:  Neuroscience       Date:  1994-02       Impact factor: 3.590

Review 5.  Diaschisis.

Authors:  J S Meyer; K Obara; K Muramatsu
Journal:  Neurol Res       Date:  1993-12       Impact factor: 2.448

6.  Effect of the NMDA antagonist MK-801 on local cerebral blood flow in focal cerebral ischaemia in the rat.

Authors:  C K Park; D G Nehls; G M Teasdale; J McCulloch
Journal:  J Cereb Blood Flow Metab       Date:  1989-10       Impact factor: 6.200

7.  The effects of N-methyl-D-aspartate receptor blockade with MK-801 upon the relationship between cerebral blood flow and glucose utilisation.

Authors:  D G Nehls; C K Park; A G MacCormack; J McCulloch
Journal:  Brain Res       Date:  1990-03-19       Impact factor: 3.252

8.  Excitatory amino acid receptors coupled to the nitric oxide/cyclic GMP pathway in rat cerebellum during development.

Authors:  E Southam; S J East; J Garthwaite
Journal:  J Neurochem       Date:  1991-06       Impact factor: 5.372

9.  Nitric oxide mediates vasodilatation in response to activation of N-methyl-D-aspartate receptors in brain.

Authors:  F M Faraci; K R Breese
Journal:  Circ Res       Date:  1993-02       Impact factor: 17.367

10.  Competitive (AP7) and non-competitive (MK-801) NMDA receptor antagonists differentially alter glucose utilization in rat cortex.

Authors:  D W Clow; S J Lee; R P Hammer
Journal:  Synapse       Date:  1991-04       Impact factor: 2.562

View more
  5 in total

1.  Effects of blockade of ionotropic glutamate receptors on blood-brain barrier disruption in focal cerebral ischemia.

Authors:  Xia Liu; Christine Hunter; Harvey R Weiss; Oak Z Chi
Journal:  Neurol Sci       Date:  2010-03-09       Impact factor: 3.307

2.  Effect of AMPA on cerebral cortical oxygen balance of ischemic rat brain.

Authors:  U Narayanan; O Z Chi; X Liu; H R Weiss
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

Review 3.  Mechanisms involved in the cerebrovascular dilator effects of N-methyl-d-aspartate in cerebral cortex.

Authors:  David W Busija; Ferenc Bari; Ferenc Domoki; Thomas Louis
Journal:  Brain Res Rev       Date:  2007-06-12

4.  Down-regulation of AMPA glutamate receptors reduces cerebrocortical metabolic response to stimulation.

Authors:  Arabinda K Sinha; Romeu Azevedo; Oak Z Chi; Harvey R Weiss
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

5.  Effects of exogenous excitatory amino acid neurotransmitters on blood-brain barrier disruption in focal cerebral ischemia.

Authors:  Oak Z Chi; Christine Hunter; Xia Liu; Harvey R Weiss
Journal:  Neurochem Res       Date:  2009-01-06       Impact factor: 3.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.